Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07464704 · ClinicalTrials.gov registry record
Infrasensor for Early Detection of a High-grade Obstructive NSTE-ACS
A clinical trial of High Grade Obstructive NSTE-ACS, sponsored by Remote Cardiac Enablement.
- Recruiting
- Registry status
- 350
- Enrollment target
- 2
- Study locations
NCT07464704 is a study of High Grade Obstructive NSTE-ACS that is actively recruiting participants, run by Remote Cardiac Enablement. The registered enrollment target is 350 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07464704, a study of High Grade Obstructive NSTE-ACS, is actively recruiting participants, sponsored by Remote Cardiac Enablement.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this prospective, cross-sectional, multicenter pivotal trial study is to validate Infrasensor's clinical performance for the detection of high grade obstructive NSTE-ACS. High-grade obstructive NSTE-ACS is defined as an acute coronary syndrome in which severe obstructive coronary artery disease, including total coronary artery occlusion is present. Study Endpoints Primary Endpoint: Infrasensor performance (Lower bound of 95% CI for sensitivity, specificity) between device detection of high-grade obstructive NSTE-ACS and angiographic diagnosis of High-grade obstructive CAD defined as the aggregate of \>50% left main stenosis, or \>70% stenosis in 1 or more coronary arteries and/or emergent revascularization. Secondary Endpoint: Infrasensor performance (positive and negative predictive values, and overall accuracy).
Conditions Studied
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07464704
The ClinicalTrials.gov registry entry for NCT07464704 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Remote Cardiac Enablement, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Grade Obstructive NSTE-ACS appearing as the primary indexed condition, and to 0 interventions.
NCT07464704 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT07464704 about?
NCT07464704 is a clinical study titled "Infrasensor for Early Detection of a High-grade Obstructive NSTE-ACS". The objective of this prospective, cross-sectional, multicenter pivotal trial study is to validate Infrasensor's clinical performance for the detection of high grade obstructive NSTE-ACS. High-grade obstructive NSTE-ACS is defined as an acute coronary syndrome in which severe obstructive coronary ar...
What is the current status of trial NCT07464704?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2025-12-30. Estimated completion is 2026-07.
What conditions does trial NCT07464704 study?
This clinical trial studies the following conditions: High Grade Obstructive NSTE-ACS.
Who is sponsoring clinical trial NCT07464704?
This trial is sponsored by Remote Cardiac Enablement, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07464704 being conducted?
This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.